RNS Number:2839P
Celsis International PLC
26 July 2005


                            CELSIS INTERNATIONAL PLC

                        AGM STATEMENT AND TRADING UPDATE


26 July 2005: Celsis International plc, the rapid microbial detection and
analytical services company, will today hold its Annual General Meeting.  Dr
Jack Rowell, Non Executive Chairman of Celsis, will make the following comments
on trading:

"In the year ended 31 March 2005, Celsis delivered another set of strong
financial results, with substantial increases in both revenues and profit.  As a
result of this, the dividend was raised by 18.6% to 1.02 cents per share.  I am
pleased to report that the current financial year has started well.

"Our Product Group, which provides diagnostic systems to check the quality of
products bound for consumers, has continued its strong growth as customers
increasingly adopt our rapid microbial testing systems.  We have seen heightened
interest in our new RapiScreen(TM) Biologics testing system for vaccine
manufacturers in both the EU and US and we continue to build upon our GCAM
(Global Corporate Account Management) strategy to further develop our business
worldwide.

"Our Laboratory Group is benefiting from the trend amongst pharmaceutical and
biopharmaceutical companies to increase their outsourcing spend on analytical
services.  Our Chemical Sciences business has shown strong progress so far this
year, building on the new contract wins and excellent results announced at our
year end.  We have also seen positive results from the Biological Sciences
business unit as we continue to concentrate our business development efforts
towards higher margin services.

"We recently announced the consolidation of the Company's ordinary share
capital, whereby existing 1p ordinary shares in the Company are being
consolidated into ordinary shares of 5p each on the basis of one new ordinary
share for every five existing shares.  We believe this is a positive step for
Celsis and its shareholders as it should improve the liquidity of Celsis shares
and make the Company more attractive to potential investors, especially in the
US.  In turn, it will also help us to make acquisitions for shares if we wish to
do so in the future.

"We look forward with confidence to another year of significant growth from both
our Product and Laboratory Groups, as markets in both areas continue to expand.
Our strong financial position means that we are well positioned to develop our
product and service offerings for the future.  We will, however, remain
disciplined in our approach when considering potential new business
opportunities to ensure long term shareholder value."


Enquiries:


Celsis International plc                                      Tel: 01638 600 151
Jay LeCoque, Chief Executive Officer
Jenny Parsons, Corporate Communications


Financial Dynamics                                            Tel: 020 7831 3113
Ben Atwell
Lucy Briggs


Notes to editors

Celsis International plc

Celsis International plc is a rapid microbial detection and analytical services
company operating through two divisions, the Product Group and the Laboratory
Group.

Using its proprietary enzyme technology, the Product Group is the world leader
in the provision of diagnostic systems for the rapid detection of microbial
contamination.  It works in close collaboration with many of the world's leading
pharmaceutical, personal care and beverage companies, ensuring the safety and
quality of products bound for consumers.  The Laboratory Group provides
outsourced analytical testing services to pharmaceutical and biopharmaceutical
companies to ensure the stability and chemical composition of their products.

In addition to ensuring product quality and safety for consumers, both divisions
have the capacity to deliver substantial cost savings to Celsis' customers.  By
reducing the time it takes to test and release raw materials and finished goods
to the market place, Celsis' products facilitate increased manufacturing
productivity and improved supply chain management.

Celsis International plc is listed on the London Stock Exchange (CEL.L).
Further information can be found on the Company's website at www.celsis.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGMSEUFMISISELW
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Celadon Pharmaceuticals Charts.
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Celadon Pharmaceuticals Charts.